Can we predict myeloma before it starts? new study aims to find out

NCT ID NCT03689595

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

The PROMISE study is enrolling 30,000 people at high risk for multiple myeloma, including African Americans and those with a family history of blood cancers. Participants provide blood samples so researchers can track changes over time and identify who progresses to myeloma. The goal is to better understand risk factors and potentially catch the disease earlier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help identify who is most likely to develop multiple myeloma, enabling earlier monitoring or intervention.
What could go wrong: This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take years to emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance plasma cell myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.